<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01075178</url>
  </required_header>
  <id_info>
    <org_study_id>M03-681</org_study_id>
    <nct_id>NCT01075178</nct_id>
  </id_info>
  <brief_title>Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease</brief_title>
  <official_title>Palivizumab (SynagisÂ®) Post-marketing Surveillance Cohort Study in Children &lt; 24 Months of Age With Hemodynamically Significant Congenital Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective medical record review study of specific adverse events in children with
      congenital heart disease who received palivizumab for prophylaxis of serious respiratory
      syncytial virus infection and control subjects that did not receive palivizumab
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, non-interventional, retrospective cohort study of infants with
      hemodynamically significant congenital heart disease (HSCHD) who were less than 24 months of
      age when the first dose of palivizumab was administered (CASES), and infants who were
      diagnosed with hemodynamically significant congenital heart disease but did not receive
      palivizumab in a historical respiratory syncytial virus (RSV) season during the first 24
      months of life (CONTROLS). CASES are matched to CONTROLS based on RSV season, age, type of
      cardiac lesion, and type of prior corrective cardiac surgery. Subject medical records are
      reviewed for occurrences of the clinical end points of infection, arrhythmia, and/or death
      that meet criteria for serious adverse events. The groups will be compared for number and
      percent of subjects who experience these primary serious adverse events (both individually
      and collectively) during a defined 8-month chart review period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Infection, Serious Arrhythmia and/or Death</measure>
    <time_frame>8-month chart review period in CASES and CONTROLS</time_frame>
    <description>The number of subjects who experienced at least 1 event of infection, arrhythmia, or death meeting any of the criteria for a serious adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Infection.</measure>
    <time_frame>8-month chart review period in CASES and CONTROLS</time_frame>
    <description>The number of subjects who experienced at least 1 event of infection meeting any of the criteria for a serious adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Arrhythmia</measure>
    <time_frame>8-month chart review period in CASES and CONTROLS</time_frame>
    <description>The number of subjects who experienced at least 1 event of arrhythmia meeting any of the criteria for a serious adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Death</measure>
    <time_frame>8-month chart review period in CASES and CONTROLS</time_frame>
    <description>The number of subjects who died</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">2036</enrollment>
  <condition>Severe Respiratory Syncytial Virus Infection</condition>
  <arm_group>
    <arm_group_label>Palivizumab-treated subjects (CASES)</arm_group_label>
    <description>HSCHD infants, &lt;2 yrs old at first dose of palivizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-palivizumab-treated subjects (CONTROLS)</arm_group_label>
    <description>HSCHD infants, &lt;2 yrs old that did not receive palivizumab</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Children less than 24 months of age with hemodynamically significant congenital heart
        disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must have documented hemodynamically significant congenital heart disease
             (Note: Children with uncomplicated small atrial or ventricular septal defects or
             patent ductus arteriosus are not eligible).

          2. Subject must have unoperated or partially corrected congenital heart disease.

          3. Subject must have received at least one dose of palivizumab for prophylaxis during the
             Respiratory Syncytial Virus season - September 1 through April 30 (CASES), or would
             have been considered eligible for palivizumab prophylaxis (CONTROLS).

          4. Subject must be &lt; 24 months of age at the time of the first dose of palivizumab
             prophylaxis (CASES) or &lt; 32 months of age at the end of the assigned Respiratory
             Syncytial Virus season in which they would have been eligible to receive palivizumab
             if the drug had been approved in the European Union (CONTROLS).

          5. Subject's parent, guardian, or legal representative has voluntarily signed and dated a
             Release of Information Form to allow the review of medical records and collection of
             pertinent study data.

        Exclusion Criteria:

          1. Subject was contraindicated for treatment with palivizumab according to the current
             European product label.

          2. Subject had full correction of Congenital Heart Disease.

          3. Subject received palivizumab before approval for use in Congenital Heart Disease
             (CASES), or subject received palivizumab at any time (CONTROLS).

          4. Subject has already been included in this study in a prior Respiratory Syncytial Virus
             season.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Campbell, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Director, Abbott Laboratories</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6263</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7956</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 9403</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 17821</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 18602</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 18601</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6244</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6261</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6245</name>
      <address>
        <city>Paris</city>
        <zip>CEDEX 15</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator#6260</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6280</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 9621</name>
      <address>
        <city>Berlin</city>
        <zip>10779</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 16361</name>
      <address>
        <city>Braunschweig</city>
        <zip>38102</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6283</name>
      <address>
        <city>Duisburg</city>
        <zip>47137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6272</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6271</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8277</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 11182</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6249</name>
      <address>
        <city>St. Augustin</city>
        <zip>53757</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6274</name>
      <address>
        <city>Campobasso</city>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6276</name>
      <address>
        <city>Florence</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4703</name>
      <address>
        <city>Naples</city>
        <zip>80100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4910</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 14681</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 14802</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6275</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 13102</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6270</name>
      <address>
        <city>Krakow</city>
        <zip>3-663</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 12222</name>
      <address>
        <city>Warsaw</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 14682</name>
      <address>
        <city>Ljubljana</city>
        <zip>1525</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5372</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 15381</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 15702</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 15261</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6282</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 13941</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5023</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=23151&amp;CFID</url>
  </link>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2010</study_first_submitted>
  <study_first_submitted_qc>February 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2010</study_first_posted>
  <results_first_submitted>January 28, 2011</results_first_submitted>
  <results_first_submitted_qc>January 28, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 24, 2011</results_first_posted>
  <last_update_submitted>March 18, 2011</last_update_submitted>
  <last_update_submitted_qc>March 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Andrew L. Campbell, M.D., Medical Director</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Infection</keyword>
  <keyword>Arrhythmia</keyword>
  <keyword>Death</keyword>
  <keyword>Palivizumab</keyword>
  <keyword>Safety</keyword>
  <keyword>Hemodynamically Significant Congenital Heart Disease</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Observational</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palivizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Infants diagnosed with hemodynamically significant congenital heart disease who were less than 24 months of age when first dosed with palivizumab (CASES) were compared for the occurrence of serious adverse events over an 8-month chart review period with matched infants who did not receive palivizumab during the first 24 months of life (CONTROLS).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Palivizumab-treated Subjects (CASES)</title>
          <description>HSCHD infants, &lt;2 yrs old at first dose of palivizumab</description>
        </group>
        <group group_id="P2">
          <title>Non-palivizumab-treated Subjects (CONTROLS)</title>
          <description>HSCHD infants, &lt;2 yrs old that did not receive palivizumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Subject Matching</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1148">eligible for matching</participants>
                <participants group_id="P2" count="1421">eligible for matching</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1018">subjects matched</participants>
                <participants group_id="P2" count="1018">subjects matched</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="403"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>eligible but not matched</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="403"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Subject Chart Review</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1018">subjects matched</participants>
                <participants group_id="P2" count="1018">subjects matched</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1009">subjects in full analysis set</participants>
                <participants group_id="P2" count="1009">subjects in full analysis set</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>died before chart review period</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>no data collected due to site closure</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>matched partner excluded (reasons above)</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Palivizumab-treated Subjects (CASES)</title>
          <description>HSCHD infants, &lt;2 yrs old at first dose of palivizumab</description>
        </group>
        <group group_id="B2">
          <title>Non-palivizumab-treated Subjects (CONTROLS)</title>
          <description>HSCHD infants, &lt;2 yrs old that did not receive palivizumab</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1009"/>
            <count group_id="B2" value="1009"/>
            <count group_id="B3" value="2018"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="651"/>
                    <measurement group_id="B2" value="656"/>
                    <measurement group_id="B3" value="1307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="358"/>
                    <measurement group_id="B2" value="353"/>
                    <measurement group_id="B3" value="711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.4" spread="4.91"/>
                    <measurement group_id="B2" value="5.4" spread="5.05"/>
                    <measurement group_id="B3" value="5.4" spread="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="437"/>
                    <measurement group_id="B2" value="462"/>
                    <measurement group_id="B3" value="899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="572"/>
                    <measurement group_id="B2" value="547"/>
                    <measurement group_id="B3" value="1119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B3" value="399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="284"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="242"/>
                    <measurement group_id="B3" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac lesion</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Cyanotic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="488"/>
                    <measurement group_id="B2" value="487"/>
                    <measurement group_id="B3" value="975"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acyanotic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="521"/>
                    <measurement group_id="B2" value="522"/>
                    <measurement group_id="B3" value="1043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Corrective cardiac surgery</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="484"/>
                    <measurement group_id="B2" value="485"/>
                    <measurement group_id="B3" value="969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partially corrected congenital heart disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="525"/>
                    <measurement group_id="B2" value="521"/>
                    <measurement group_id="B3" value="1046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fully corrected congenital heart disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Infection, Serious Arrhythmia and/or Death</title>
        <description>The number of subjects who experienced at least 1 event of infection, arrhythmia, or death meeting any of the criteria for a serious adverse event</description>
        <time_frame>8-month chart review period in CASES and CONTROLS</time_frame>
        <population>The population analyzed included the full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Palivizumab-treated Subjects (CASES)</title>
            <description>HSCHD infants, &lt;2 yrs old at first dose of palivizumab</description>
          </group>
          <group group_id="O2">
            <title>Non-palivizumab-treated Subjects (CONTROLS)</title>
            <description>HSCHD infants, &lt;2 yrs old that did not receive palivizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Infection, Serious Arrhythmia and/or Death</title>
          <description>The number of subjects who experienced at least 1 event of infection, arrhythmia, or death meeting any of the criteria for a serious adverse event</description>
          <population>The population analyzed included the full analysis set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1009"/>
                <count group_id="O2" value="1009"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303"/>
                    <measurement group_id="O2" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that the odds ratio was greater than or equal to 2. The planned sample size of 2000 participants (1000 participants in each group) provided greater than 90% power to determine non-inferiority based on the odds ratio less than 2.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was assessed with a 95% 1-sided confidence interval for which the upper bound of the difference in the event rates (CASES minus CONTROLS) will correspond to an odds ratio less than 2 (that is, the odds ratio calculated at the upper confidence bound of the difference in event rates will be less than 2).</non_inferiority_desc>
            <param_type>Observed odds ratio</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>0.96</ci_upper_limit>
            <estimate_desc>Result provided for &quot;95% Confidence Interval (1-Sided)&quot; is the odds ratio calculated at the upper bound of the 1-sided 95% confidence interval for the difference in event rates (CASES minus CONTROLS).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Infection.</title>
        <description>The number of subjects who experienced at least 1 event of infection meeting any of the criteria for a serious adverse event</description>
        <time_frame>8-month chart review period in CASES and CONTROLS</time_frame>
        <population>The population analyzed included the full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Palivizumab-treated Subjects (CASES)</title>
            <description>HSCHD infants, &lt;2 yrs old at first dose of palivizumab</description>
          </group>
          <group group_id="O2">
            <title>Non-palivizumab-treated Subjects (CONTROLS)</title>
            <description>HSCHD infants, &lt;2 yrs old that did not receive palivizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Infection.</title>
          <description>The number of subjects who experienced at least 1 event of infection meeting any of the criteria for a serious adverse event</description>
          <population>The population analyzed included the full analysis set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1009"/>
                <count group_id="O2" value="1009"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281"/>
                    <measurement group_id="O2" value="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that the odds ratio was greater than or equal to 2. The planned sample size of 2000 participants (1000 participants in each group) provided greater than 90% power to determine non-inferiority based on the odds ratio less than 2.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was assessed with a 95% 1-sided confidence interval for which the upper bound of the difference in the event rates (CASES minus CONTROLS) will correspond to an odds ratio less than 2 (that is, the odds ratio calculated at the upper confidence bound of the difference in event rates will be less than 2).</non_inferiority_desc>
            <param_type>Observed odds ratio</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>0.95</ci_upper_limit>
            <estimate_desc>Result provided for &quot;95% Confidence Interval (1-Sided)&quot; is the odds ratio calculated at the upper bound of the 1-sided 95% confidence interval for the difference in event rates (CASES minus CONTROLS).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Arrhythmia</title>
        <description>The number of subjects who experienced at least 1 event of arrhythmia meeting any of the criteria for a serious adverse event</description>
        <time_frame>8-month chart review period in CASES and CONTROLS</time_frame>
        <population>The population analyzed included the full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Palivizumab-treated Subjects (CASES)</title>
            <description>HSCHD infants, &lt;2 yrs old at first dose of palivizumab</description>
          </group>
          <group group_id="O2">
            <title>Non-palivizumab-treated Subjects (CONTROLS)</title>
            <description>HSCHD infants, &lt;2 yrs old that did not receive palivizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Arrhythmia</title>
          <description>The number of subjects who experienced at least 1 event of arrhythmia meeting any of the criteria for a serious adverse event</description>
          <population>The population analyzed included the full analysis set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1009"/>
                <count group_id="O2" value="1009"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that the odds ratio was greater than or equal to 2. The planned sample size of 2000 participants (1000 participants in each group) provided greater than 90% power to determine non-inferiority based on the odds ratio less than 2.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was assessed with a 95% 1-sided confidence interval for which the upper bound of the difference in the event rates (CASES minus CONTROLS) will correspond to an odds ratio less than 2 (that is, the odds ratio calculated at the upper confidence bound of the difference in event rates will be less than 2).</non_inferiority_desc>
            <param_type>Observed odds ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>1.64</ci_upper_limit>
            <estimate_desc>Result provided for &quot;95% Confidence Interval (1-Sided)&quot; is the odds ratio calculated at the upper bound of the 1-sided 95% confidence interval for the difference in event rates (CASES minus CONTROLS).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Death</title>
        <description>The number of subjects who died</description>
        <time_frame>8-month chart review period in CASES and CONTROLS</time_frame>
        <population>The population analyzed included the full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Palivizumab-treated Subjects (CASES)</title>
            <description>HSCHD infants, &lt;2 yrs old at first dose of palivizumab</description>
          </group>
          <group group_id="O2">
            <title>Non-palivizumab-treated Subjects (CONTROLS)</title>
            <description>HSCHD infants, &lt;2 yrs old that did not receive palivizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Death</title>
          <description>The number of subjects who died</description>
          <population>The population analyzed included the full analysis set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1009"/>
                <count group_id="O2" value="1009"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that the odds ratio was greater than or equal to 2. The planned sample size of 2000 participants (1000 participants in each group) provided greater than 90% power to determine non-inferiority based on the odds ratio less than 2.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was assessed with a 95% 1-sided confidence interval for which the upper bound of the difference in the event rates (CASES minus CONTROLS) will correspond to an odds ratio less than 2 (that is, the odds ratio calculated at the upper confidence bound of the difference in event rates will be less than 2).</non_inferiority_desc>
            <param_type>Observed odds ratio</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>2.19</ci_upper_limit>
            <estimate_desc>Result provided for &quot;95% Confidence Interval (1-Sided)&quot; is the odds ratio calculated at the upper bound of the 1-sided 95% confidence interval for the difference in event rates (CASES minus CONTROLS).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8-month chart review period</time_frame>
      <desc>Only serious adverse events of infection, arrhythmia, and death were collected and assessed as part of the study; other (non-serious) adverse events were not collected or assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Palivizumab-treated Subjects (CASES)</title>
          <description>HSCHD infants, &lt;2 yrs old at first dose of palivizumab</description>
        </group>
        <group group_id="E2">
          <title>Non-palivizumab-treated Subjects (CONTROLS)</title>
          <description>HSCHD infants, &lt;2 yrs old that did not receive palivizumab</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="303" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="349" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Nodal arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Nodal rhythm</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Congenital pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Heart disease congenital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Hypoplastic left heart syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Necrotising colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Heart transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Acinetobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Bacillus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Candida sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Candiduria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Catheter sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Dermatitis infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Endicarditis enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Enterobacter sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Gastric infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Gastroenteritis adenovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Haemophilus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Incision site abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Metapneumovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Moraxella infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Nosocomial infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Parainfluenza virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Pneumocystitis jiroveci infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Post procedural pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Serratia infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Stenotrophomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Tracheostomy infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Viral tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Wound infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cardiac pacemaker malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile toxin test</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Lung consolidation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hangnail</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemodynamic instability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1009"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Only serious adverse events of infection and arrhythmia as well as deaths were collected in this study. The criterion for non-inferiority was not met for death, most likely because the reported mortality rates were lower than expected in both groups.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>Abbott</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

